Retatrutide: Triple-Agonist Drug with 24% Weight Loss
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, producing 24.2% weight loss in Phase 2 trials — beyond any current obesity drug.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on April 22, 2026
Our medical review process ensures clinical accuracy and patient safety.
Retatrutide is poised to redefine what's possible in obesity pharmacotherapy. Where semaglutide (Wegovy) produces roughly 15% body weight reduction and tirzepatide achieves around 21%, this next-generation triple agonist delivered 24.2% mean weight loss at 48 weeks in its Phase 2 trial — numbers that approach the outcomes typically reserved for bariatric surgery.
Developed by Eli Lilly, retatrutide simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. That third receptor — glucagon — separates it from every approved obesity drug currently on the market and may explain why its efficacy looks categorically different from its predecessors.
What Is Retatrutide and How Does It Work?
Retatrutide (LY3437943) is a once-weekly subcutaneous injection that acts as a unimolecular triple agonist at GLP-1, GIP, and glucagon receptors. The molecule is a 39-amino acid peptide linked to a C20 fatty diacid moiety, which extends its half-life and allows for weekly dosing.
The Three-Receptor Mechanism
Each receptor contributes a distinct metabolic effect:
| Receptor | Primary Actions |
|---|---|
| GLP-1 | Reduces appetite, slows gastric emptying, improves insulin secretion |
| GIP | Enhances insulin and glucagon secretion, promotes fat storage regulation |
| Glucagon | Increases energy expenditure, promotes lipolysis, reduces hepatic fat |
The glucagon receptor component is particularly consequential. Glucagon agonism increases resting metabolic rate and promotes the breakdown of fat in the liver — effects that GLP-1 and GIP receptor agonists cannot replicate. The net result is a drug that suppresses appetite, improves insulin sensitivity, and raises energy expenditure simultaneously.
Evidence: "Agonism of GCG receptors increases energy expenditure and lipolysis, decreases lipogenesis, and increases insulin secretion, complementing the appetite-suppressing effects of GLP-1 and GIP receptor activation." — Triple Agonism Based Therapies for Obesity. PMC. 2025. PMC12304053
Relative to natural GLP-1 and glucagon, retatrutide shows lower potency at GLP-1 and glucagon receptors but enhanced potency at the GIP receptor — a deliberate pharmacological profile designed to maximize metabolic benefit while controlling gastrointestinal side effects.
Phase 2 Trial Results: What the Evidence Shows
NEJM Obesity Trial (2023)
The landmark trial was published in the New England Journal of Medicine in June 2023. It enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related complication, across multiple dose groups over 48 weeks.
Weight loss by dose at 48 weeks:
| Dose | Mean Weight Reduction | ≥5% Loss | ≥10% Loss | ≥15% Loss |
|---|---|---|---|---|
| Placebo | −2.1% | 27% | 9% | 2% |
| 1 mg | −8.7% | — | — | — |
| 4 mg | −17.1% | 92% | 75% | 60% |
| 8 mg | −22.8% | 100% | 91% | 75% |
| 12 mg | −24.2% | 100% | 93% | 83% |
At the highest tested dose of 12 mg, every single participant achieved at least 5% weight loss, and 83% surpassed the 15% threshold — a benchmark that defines clinically meaningful long-term metabolic improvement.
Evidence: "At 48 weeks, the least-squares mean percentage change in body weight was −24.2% in the 12-mg group, as compared with −2.1% in the placebo group." — Jastreboff AM, et al. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2301972
The trial also documented reductions in waist circumference, blood pressure, fasting insulin, and triglycerides — metabolic improvements independent of weight loss alone.
Phase 2 Type 2 Diabetes Trial (Lancet 2023)
A separate Phase 2 trial published in The Lancet evaluated retatrutide specifically in adults with type 2 diabetes. This population typically shows attenuated weight loss responses to GLP-1 receptor agonists compared to those without diabetes — yet retatrutide still delivered 16.9% mean weight loss after 36 weeks at the highest dose.
Glycemic outcomes were equally striking:
- HbA1c improved by a mean of 2.2 percentage points
- 82% of participants reached HbA1c ≤ 6.5%, the threshold for diabetes remission
- Fasting glucose fell significantly across all active dose groups
Evidence: "In people with type 2 diabetes, retatrutide showed clinically meaningful improvements in glycaemic control and robust reductions in bodyweight, with a safety profile consistent with GLP-1 receptor agonists." — Rosenstock J, et al. Lancet. 2023. DOI: 10.1016/S0140-6736(23)01053-X
Retatrutide vs. Other GLP-1 Medications
For context, a direct comparison against currently approved agents illustrates the step-change in efficacy that retatrutide represents.
| Drug | Mechanism | Peak Weight Loss |
|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% at 68 weeks |
| Tirzepatide (Zepbound) | GLP-1/GIP dual agonist | ~20–22% at 72 weeks |
| Retatrutide | GLP-1/GIP/Glucagon triple agonist | ~24% at 48 weeks |
Retatrutide's 48-week data already exceeds tirzepatide's 72-week results — and the trial was not extended to test its ceiling. The addition of glucagon receptor agonism appears to provide a meaningful efficacy increment beyond what dual-agonism achieves. For a full comparison of the current generation, see Tirzepatide vs Semaglutide: Which Is More Effective?.
A 2025 systematic review and meta-analysis confirmed these findings across pooled trial data.
Evidence: "Retatrutide's efficacy is enhanced through the combination of GLP-1, GIP, and glucagon receptor activation, resulting in significantly greater reductions in body weight compared to currently approved GLP-1 receptor agonists." — Khalifa M, et al. Front Endocrinol. 2025. PubMed
Metabolic Benefits Beyond Weight Loss
Liver Health: Up to 82% Reduction in Liver Fat
A Phase 2a trial published in Nature Medicine in 2024 examined retatrutide specifically in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as non-alcoholic fatty liver disease (NAFLD).
The results were among the most striking in liver disease pharmacology:
| Dose | Mean Reduction in Liver Fat | Achieved Normal Liver Fat (<5%) |
|---|---|---|
| Placebo | +0.3% | 0% |
| 1 mg | −42.9% | 27% |
| 4 mg | −57.0% | 52% |
| 8 mg | −81.4% | 79% |
| 12 mg | −82.4% | 86% |
At the 12 mg dose, 86% of participants normalized liver fat content within 24 weeks. This would represent a treatment breakthrough for a condition that currently has limited pharmacological options and affects an estimated 25% of the global population.
Evidence: "Retatrutide treatment resulted in up to 82% relative reduction in liver fat content, with 86% of participants in the 12 mg group achieving liver fat normalization at 24 weeks." — Sanyal AJ, et al. Nature Medicine. 2024. DOI: 10.1038/s41591-024-03018-2
The glucagon receptor component is mechanistically important here. Glucagon agonism directly promotes hepatic fatty acid oxidation and reduces lipogenesis — the liver-specific pathways driving steatosis — independent of weight loss.
Cardiovascular Markers
Across trials, retatrutide consistently improved:
- Systolic blood pressure: reductions of 6–10 mmHg
- Triglycerides: reductions of 30–40%
- HDL cholesterol: increases in most dose groups
- Waist circumference: reductions correlating with visceral fat loss
Phase 3 cardiovascular outcomes trials are underway to determine whether these surrogate marker improvements translate to reduced major adverse cardiovascular events (MACE), as demonstrated with semaglutide in the SELECT trial.
Side Effects and Safety Profile
Across Phase 2 trials, the safety profile of retatrutide was broadly consistent with that of approved GLP-1 receptor agonists. The most common adverse events were gastrointestinal and dose-dependent:
- Nausea: 40–60% in higher-dose groups, predominantly mild-to-moderate and transient
- Vomiting: 20–30%, more common during dose escalation
- Diarrhea: 20–30%
- Constipation: 10–20%
These side effects were most prevalent during the dose-escalation phase and diminished over time. Discontinuation rates due to adverse events were in the 5–10% range across active groups — similar to tirzepatide trial data.
Importantly, no clinically significant increase in heart rate was observed, a concern that has been raised with some GLP-1/glucagon combination approaches. Pancreatic and thyroid safety signals were not identified in Phase 2, though Phase 3 trials with larger populations and longer follow-up are required to characterize rare adverse events.
What Phase 3 Looks Like — and When It Might Be Available
Phase 3 trials for retatrutide are currently enrolling under Eli Lilly's TRIUMPH program:
- TRIUMPH-1: Adults with obesity, primary endpoint 72-week weight loss
- TRIUMPH-2: Type 2 diabetes, HbA1c and weight co-primary endpoints
- TRIUMPH-3: Cardiovascular outcomes in high-risk patients
- TRIUMPH-NASH: MASLD/MASH, histological resolution endpoints
Phase 2 data suggests Phase 3 will confirm strong efficacy. Regulatory submission could occur as early as 2026, with potential FDA approval in 2026–2027 — making retatrutide the next major obesity drug to market after tirzepatide's approval as Zepbound in 2023.
The question for patients and clinicians is not whether retatrutide works, but where it fits within an expanding therapeutic landscape. Its combination of superior weight loss, liver benefit, and glycemic control may make it the preferred choice for patients with obesity and comorbid MASLD, type 2 diabetes, or significant cardiovascular risk — particularly those who have not achieved treatment goals on current dual-agonist therapy. Patients currently on semaglutide who are concerned about long-term weight maintenance might also review Weight Regain After Stopping GLP-1 Medications in context of the decision to escalate therapy.
Key Takeaways
- Retatrutide is a once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors — no approved drug currently activates all three.
- Phase 2 data showed 24.2% mean weight loss at 48 weeks at the 12 mg dose, with 100% of participants achieving ≥5% weight loss.
- In type 2 diabetes, retatrutide produced 16.9% weight loss and reduced HbA1c by 2.2 percentage points over 36 weeks.
- A separate trial demonstrated 82% liver fat reduction in MASLD patients, with 86% achieving normal liver fat at the highest dose.
- Side effects are primarily gastrointestinal and transient; the overall safety profile is consistent with approved GLP-1 receptor agonists.
- Phase 3 TRIUMPH trials are ongoing; FDA approval is anticipated in 2026–2027 pending trial completion.
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet. 2023;402(10401):529-544. DOI: 10.1016/S0140-6736(23)01053-X
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. DOI: 10.1038/s41591-024-03018-2
- Khalifa M, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis. Front Endocrinol. 2025. PubMed
- Triple Agonism Based Therapies for Obesity. PMC Review. 2025. PMC
Last updated: 2026-04-22
Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.